
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved.
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved.
| Issuer/Instrument | |
% to Net Assets |
|---|---|---|
| Equity & Equity related | ||
| Pharmaceuticals and Biotechnology | 74.45 | |
| Sun Pharmaceuticals Industries Ltd. | 13.91 | |
| JB CHEMICALS & PHARMACEUTICALS LTD. | 7.51 | |
| Divi s Laboratories Ltd. | 6.05 | |
| ACUTAAS CHEMICALS LTD | 5.09 | |
| Lupin Ltd. | 4.19 | |
| Cipla Ltd. | 3.32 | |
| SAI LIFE SCIENCES LIMITED | 3.08 | |
| Aurobindo Pharma Ltd. | 2.80 | |
| Ajanta Pharma Ltd. | 2.66 | |
| JUBILANT PHARMOVA LIMITED | 2.49 | |
| Glenmark Pharmaceuticals Ltd | 2.41 | |
| Alkem Laboratories Ltd. | 2.40 | |
| ANTHEM BIOSCIENCES LTD | 2.37 | |
| GLAND PHARMA LIMITED | 2.11 | |
| CORONA REMEDIES LIMITED | 1.93 | |
| EMCURE PHARMACEUTICALS LIMITED | 1.80 | |
| Marksans Pharma Ltd | 1.77 | |
| RUBICON RESEARCH LTD | 1.75 | |
| MANKIND PHARMA LTD | 1.72 | |
| DR REDDYS LABORATORIES LTD. | 1.42 | |
| Zydus Lifesciences Limited | 1.38 | |
| INNOVA CAPTABS LTD | 1.20 | |
| ORCHID PHARMA LTD. | 1.09 | |
| Healthcare Services | 23.66 | |
| MAX HEALTHCARE INSTITUTE LTD. | 6.96 | |
| Fortis Healthcare India Ltd | 4.67 | |
| PARK MEDI WORLD LIMITED (PARK HOSPITAL) | 3.48 | |
| Apollo Hospitals Enterprises Ltd. | 3.35 | |
| KRISHNA INSTITUTE OF MEDICAL | 2.81 | |
| YATHARTH HOSPITAL AND TRAUMA CARE SERVICES LTD | 1.26 | |
| RAINBOW CHILDRENS MEDICARE LTD | 1.13 | |
| Healthcare Equipment and Supplies | 1.02 | |
| LAXMI DENTAL LIMITED | 1.02 | |
| Insurance | 0.22 | |
| MEDI ASSIST HEALTHCARE SERVICES LIMITED | 0.22 | |
| Equity & Equity related - Total | 99.35 | |
| Triparty Repo | 1.24 | |
| Net Current Assets/(Liabilities) | -0.59 | |
| Grand Total | 100.00 | |
| | ||
| Monthly SIP of Rs 10000 | Since Inception | 1 Year |
| Total amount invested (₹) | 2,80,000 | 1,20,000 |
| Total Value as on Mar 30, 2026 (₹) | 2,94,222 | 1,19,073 |
| Scheme Returns (%) | 4.19 | -1.44 |
| Nifty Healthcare Index (TRI) Returns (%) | 5.92 | -0.99 |
| Alpha* | -1.73 | -0.46 |
| Nifty Healthcare Index (TRI) (₹)# | 3,00,201 | 1,19,368 |
| Nifty 50 (TRI) (₹)^ | 2,64,574 | 1,07,836 |
| Nifty 50 (TRI) Returns (%) | -4.66 | -18.42 |
| Regular | Direct | |
| Growth | Rs13.1484 | Rs13.6549 |
| IDCW | Rs13.1526 | Rs13.6538 |
A) Regular Plan B) Direct Plan
Options: Growth and Income Distribution
cum capital withdrawal (IDCW) (Payout and
Reinvestment)
| Fund Manager* |
Ms. Shibani Sircar Kurian, (Effective till March 31, 2026) Mr. Abhishek Bisen & Mr. Dhananjay Tikariha |
| Benchmark | Nifty Healthcare Index TRI |
| Allotment date | December 11, 2023 |
| AAUM | Rs455.92 crs |
| AUM | Rs442.28 crs |
| Folio count | 32,724 |
Trustee's Discretion
| Portfolio Turnover | 25.68% |
| $Beta | 0.96 |
| $Sharpe ## | 0.33 |
| $Standard Deviation | 16.81% |
| ^^(P/E) | 38.83 |
| ^^P/BV | 5.35 |
| Large Cap | 35.01% |
| Mid Cap | 21.94% |
| Small Cap | 42.40% |
| Debt & Money Market | 0.65% |
*% of Net Asset
Initial & Additional Investment
• Rs100 and any amount thereafter
Systematic Investment Plan (SIP)
• Rs 100 and any amount thereafter
• 5 years & above
Entry Load: Nil. (applicable for all plans)
Exit Load:
• For redemption / switch out within 30
days from the date of allotment: 0.5%
• If units are redeemed or switched out on
or after 30 days from the date of allotment:
NIL
| Regular Plan: | 2.34% |
| Direct Plan: | 0.74% |


* Investors should consult their financial advisors if in doubt about whether the product is suitable for them.
For latest Riskometer, investors may refer to an addendum issued or updated on website at www.kotakmf.com